Europe — EMA
Oyavas (Bevacizumab)
Bevacizumab, the active ingredient in Oyavas, is a monoclonal antibody presented as a unknown strength/unknown form for intravenous use.
Request sourcing
What is Bevacizumab?
Bevacizumab, the active ingredient in Oyavas, is a monoclonal antibody presented as a unknown strength/unknown form for intravenous use. It targets abnormal blood vessel growth and is employed in oncology settings, particularly for adult patients with certain solid tumours. GNH USA supplies Oyavas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
GNH USA supplies Oyavas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
What is Bevacizumab used for?
Oyavas is a monoclonal antibody that acts on pathways involved in abnormal angiogenesis associated with several cancers.
- Colorectal cancer: Improves ... ... ... ... ... ... ... ... ... … ... … ... ... ... - ... .... .... .... .... .... .... .... .... ... - .... .... """""""""""""""""""""""""""""""""""""""" - ...
